Addex Pharmaceuticals discovers and develops allosteric modulators for human health and is focused on validated therapeutic targets for diseases of the central nervous system, metabolic disorders and inflammation. The Addex pipeline demonstrates the productivity and broad potential of this unparalleled platform. Subject to the completion of Phase I testing and regulatory approvals, Phase II clinical trials are expected to start around the end of 2010 in four indications for two lead products: ADX48621, an mGluR5 negative allosteric modulator (NAM), in Parkinson’s disease levodopa-induced dyskinesia (PD-LID) and focal dystonia; and ADX71149, an mGluR2 positive allosteric modulator (PAM), in schizophrenia and anxiety. ADX71149 is licensed to Ortho-McNeil-Janssen Pharmaceuticals Inc. A third product, ADX71943, GABA-B receptor PAM with potential for chronic pain, is scheduled to enter Phase I testing in 2011. In addition, Merck & Co., Inc. has licensed rights to two preclinical products: mGluR4 PAM for Parkinson's disease and mGluR5 PAM for schizophrenia. Additional preclinical discovery stage programs include: mGluR2 NAM, GLP1R PAM, IL1R1 NAM and TNFR1 NAM. Roche Venture Fund and SR-One, corporate venture arm of GlaxoSmithKline, are investors in Addex. 

selected press releases

our allosteric modulator discovery laboratories in Geneva

media and other exposure